Hester Biosciences Limited (BOM: 524669)
India
· Delayed Price · Currency is INR | Market Cap | 21.00B |
| Revenue (ttm) | 3.16B |
| Net Income (ttm) | 234.69M |
| Shares Out | 8.51M |
| EPS (ttm) | 27.73 |
| PE Ratio | 89.03 |
| Forward PE | n/a |
| Dividend | 6.00 (0.24%) |
| Ex-Dividend Date | Aug 22, 2024 |
| Volume | 231 |
| Open | 2,435.05 |
| Previous Close | 2,495.00 |
| Day's Range | 2,435.05 - 2,599.85 |
| 52-Week Range | 1,292.90 - 3,375.45 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2024 |
About Hester Biosciences
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through Poultry Healthcare, Animal Healthcare, and Petcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, marek’s disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers livestock vaccines for goat pox, peste des petits ruminants, brucella abortus, cont... [Read more]
Financial Performance
In 2023, Hester Biosciences's revenue was 3.11 billion, an increase of 11.86% compared to the previous year's 2.78 billion. Earnings were 188.89 million, a decrease of -29.06%.
Financial StatementsNews
Hester Biosciences shares surge over 11% following strong Q2 FY25 performance
Hester Biosciences’ shares soared by 11.21% today, reaching ₹2,474.65, following the announcement of robust Q2 FY25 results. The company’s strong financial performance has sparked investor confidence,...
Hester Biosciences Q2: Revenue jumps 18.8% YoY to ₹83.69 crores, PAT surges 107.4% YoY to ₹8.39 crores
Hester Biosciences, a leading player in the animal healthcare sector, has reported an impressive financial performance for Q2 FY25. The company’s consolidated results indicate strong growth in revenue...